Distributor Appointed in South Korea
December 01 2010 - 5:10AM
UK Regulatory
TIDMRGT
ReGen Signs Agreement for the Distribution of its Nutraceutical ColostrininTM in
South Korea with LG Life Sciences
01/12/2010
ReGen Therapeutics Plc ('ReGen') is pleased to announce that it has today signed
an agreement with LG Life Sciences, Ltd ('LGLS'), appointing them as the
exclusive distributor of its nutritional supplement Colostrinin(TM) in South
Korea.
LGLS is the leading pharmaceutical company based in Seoul, Korea, committed to
promoting health and well being of patients and customers. Its key therapeutic
areas include metabolic and cardiovascular diseases as well as well-being. In
parallel LGLS has a unique capability to develop and market nutraceutical
products and has a plan to distribute Colostrinin(TM) through various shopping
channels. Additional information is available on its corporate website,
www.lgls.co.kr.
This appointment is conditional upon LGLS securing import and regulatory
approval for the product. An application to gain approval should be submitted
before the end of the first quarter of 2011 but approval may take some
considerable time to achieve. LGLS will also be developing their own formulation
of Colostrinin(TM) specifically tailored to the retail market in South Korea. No
further details of the agreement will be disclosed at this time.
To date Colostrinin(TM) is marketed as a nutritional supplement to 'support
healthy brain aging and cognition in humans' in the US, Canada, Australia and
Poland under the brand name CogniSure(TM) *, in Cyprus under the brand name
Cognase(TM) **, in the UK under the brand name MemoryAid (TM) ***, in Turkey
under the brand name Dyna(TM) **** and in India under the brand name Cognate
(TM) *****
The ReGen Board regards this is a significant step for ReGen as it provides
entry into the major growth area of the world economy. It is very important in
the context of the accelerated roll out programme for Colostrinin(TM).
* Colostrinin(TM) for use as a human nutraceutical is licensed in North
America and Australasia to Metagenics Inc. of San Clemente, California
(www.metagenics.com).
Colostrinin(TM) is distributed in Poland by Tagerr Polska, an
affliate of Tagerr a professional services and trading company established in
Köln, Germany. (www.cognisure.eu)
** Colostrinin(TM) is distributed in the Republic of Cyprus by Golgi
Pharmaceuticals Ltd (www.healthybrainaging.com).
*** Colostrinin(TM) is distributed in the UK by PRG Nutraceuticals Ltd
(www.memoryaid.com)
**** Colostrinin(TM) is distributed in Turkey by Eczacibasi Ilac Pazarlama
A.S (www.eczacibasi.com)
***** Colostrinin(TM) is distributed in India by USV Ltd (www.usvindia.com )
For further information:
Percy Lomax
ReGen Therapeutics Plc
Tel No 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel No 020 7628 3396
Nick Bealer/David Scott
Alexander David
Tel No 020 7448 9820
[HUG#1467514]
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: ReGen Therapeutics Plc via Thomson Reuters ONE
Argent Biopharma (LSE:RGT)
Historical Stock Chart
From May 2024 to Jun 2024
Argent Biopharma (LSE:RGT)
Historical Stock Chart
From Jun 2023 to Jun 2024